Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
efficacy
niraparib
olaparib
ovarian cancer
rucaparib
safety
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Apr 2021
19 Apr 2021
Historique:
received:
18
03
2021
revised:
12
04
2021
accepted:
14
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP on the DNA. In this way, they inhibit single-strand DNA damage repair. These drugs have been approved in recent years for the treatment of ovarian cancer. Although they share some similarities, from the point of view of the chemical structure and pharmacodynamic, pharmacokinetic properties, these drugs also have some substantial differences. These differences may underlie the different safety profiles and activity of PARPi.
Identifiants
pubmed: 33921561
pii: ijms22084203
doi: 10.3390/ijms22084203
pmc: PMC8073512
pii:
doi:
Substances chimiques
Phthalazines
0
Piperazines
0
Poly(ADP-ribose) Polymerase Inhibitors
0
olaparib
WOH1JD9AR8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Gynecol Oncol. 2020 Nov;159(2):581-587
pubmed: 32972786
Ann Oncol. 2020 Dec;31(12):1606-1622
pubmed: 33004253
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
PLoS One. 2013;8(3):e59679
pubmed: 23555743
Nat Rev Cancer. 2010 Apr;10(4):293-301
pubmed: 20200537
Cancer Discov. 2014 Dec;4(12):1430-47
pubmed: 25252691
Science. 1997 Nov 7;278(5340):1064-8
pubmed: 9353181
Gynecol Oncol. 2021 Jan;160(1):175-181
pubmed: 33250205
Lancet Oncol. 2020 May;21(5):710-722
pubmed: 32359490
Gynecol Oncol. 2020 Dec;159(3):887-898
pubmed: 33012552
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Cancer Treat Rev. 2020 Jul;87:102040
pubmed: 32485510
Br J Cancer. 2016 Nov 22;115(11):1313-1320
pubmed: 27824811
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Rapid Commun Mass Spectrom. 2020 Feb 15;34(3):e8575
pubmed: 31499579
Cells. 2019 Dec 22;9(1):
pubmed: 31877876
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Ann Oncol. 2021 Apr;32(4):512-521
pubmed: 33453391
Invest New Drugs. 2020 Jun;38(3):765-775
pubmed: 31250355
Cell Mol Life Sci. 2014 Jan;71(2):331-48
pubmed: 23760205
PLoS One. 2014 Jun 13;9(6):e100041
pubmed: 24927325
Adv Ther. 2018 Nov;35(11):1945-1964
pubmed: 30324586
Clin Pharmacol Drug Dev. 2019 Jan;8(1):107-118
pubmed: 29799676
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cell Chem Biol. 2016 Dec 22;23(12):1490-1503
pubmed: 27866910
Nat Biotechnol. 2012 Feb 19;30(3):283-8
pubmed: 22343925
J Clin Oncol. 2019 Dec 1;37(34):3183-3191
pubmed: 31518175
Invest New Drugs. 2017 Dec;35(6):751-765
pubmed: 28303528
DNA Repair (Amst). 2019 Apr;76:20-29
pubmed: 30807923
Cancer Sci. 2012 Mar;103(3):504-9
pubmed: 22145984
PLoS One. 2015 May 28;10(5):e0124269
pubmed: 26020771
Future Oncol. 2019 Dec;15(36):4197-4206
pubmed: 31707856
Nat Commun. 2018 Feb 21;9(1):746
pubmed: 29467415
Gynecol Oncol. 2020 Oct;159(1):8-12
pubmed: 32778410
J Biol Chem. 2008 Jan 11;283(2):1197-208
pubmed: 18025084
EMBO J. 2014 Apr 16;33(8):862-77
pubmed: 24534091
Mol Cancer Ther. 2013 Jun;12(6):1002-15
pubmed: 23729402
J Clin Oncol. 2020 Oct 20;38(30):3494-3505
pubmed: 32840418
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
Cells. 2020 Jul 13;9(7):
pubmed: 32668560
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Gynecol Oncol. 2020 Oct;159(1):112-117
pubmed: 32811682
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340362
Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28
pubmed: 24579667
Annu Rev Cell Dev Biol. 2017 Oct 6;33:577-599
pubmed: 28992436
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
Lancet Haematol. 2021 Feb;8(2):e122-e134
pubmed: 33347814
Gynecol Oncol. 2020 Nov;159(2):442-448
pubmed: 32981695
J Med Chem. 2017 Feb 23;60(4):1262-1271
pubmed: 28001384
Clin Adv Hematol Oncol. 2020 Sep;18(9):550-556
pubmed: 33006584
Cell Death Differ. 2015 Jul;22(7):1144-57
pubmed: 25501596
Gynecol Oncol. 2020 Jan;156(1):38-44
pubmed: 31699415
Mol Med Rep. 2017 Dec;16(6):8076-8084
pubmed: 28983606
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Cancers (Basel). 2020 Oct 18;12(10):
pubmed: 33081005
Cell Prolif. 2016 Aug;49(4):421-37
pubmed: 27329285
Gynecol Oncol. 2021 Jan;160(1):333-345
pubmed: 33055011
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106
pubmed: 28264872
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46
pubmed: 29043410
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5
pubmed: 22493268
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Sci Rep. 2020 Feb 17;10(1):2585
pubmed: 32066817
NMR Biomed. 2017 Sep;30(9):
pubmed: 28543772
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Front Biosci (Schol Ed). 2016 Jan 01;8:123-8
pubmed: 26709902
Breast Cancer Res Treat. 2012 Jul;134(2):649-59
pubmed: 22678161
DNA Repair (Amst). 2013 Jul;12(7):529-34
pubmed: 23684799
Oncologist. 2020 Jan;25(1):e109-e119
pubmed: 31575788
Gynecol Oncol. 2018 Apr;149(1):214-220
pubmed: 29397193
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Recent Pat Anticancer Drug Discov. 2018;13(4):392-410
pubmed: 29512470
Oncologist. 2021 Jan;26(1):e164-e172
pubmed: 33017510